Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 6.4% | 14.3% | 17.7% | 15.5% | 17.6% | 13.6% | 10.8% | 11.8% | 11.7% | 13.7% | 11.3% | 7.0% | 10.0% | 9.6% | 13.5% | 16.3% | 20.2% | 31.6% | 23.3% | 21.3% |
Discover the top 20 best undervalued stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Feb 2025.
As of today, Microsoft Corp's last 12-month Return on Equity (ROE) is 18.8%, based on the financial report for Sep 30, 2024 (Q3 2024). The average annual Return on Equity (ROE) for West Pharmaceutical Services, Inc. have been 23.6% over the past three years, and 22.4% over the past five years.
As of today, West Pharmaceutical Services, Inc.'s Return on Equity (ROE) is 18.8%, which is higher than industry median of (3.2%). It indicates that West Pharmaceutical Services, Inc.'s Return on Equity (ROE) is Good.